Bavarian Nordic (OTCPK:BVNRY) has received FDA approval for its vaccine Vimkunya for the prevention of chikungunya. The virus-like particle, or VLP, vaccine is approved for people aged 12 and older.

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention for younger travelers.On track for commercial launch in the U.S. in the ...

First chikungunya vaccine approved for persons as young as 12 years old, addressing an unmet need for chikungunya prevention ...

Monocle is in Munich with the latest on the “terror attack” as the Bavarian capital kicks off its high-stakes security ...

A driver drove a car into a labor union demonstration in central Munich on Thursday, injuring 30 people including children, ...

The European Commission (EC) has already approved Valneva’s chikungunya vaccine Ixchiq for use in individuals aged 18 years ...

GN Store Nord A/S was the biggest leader among large stocks during the session, rising 8.4%, and BioGaia AB Series B rose 6.2%. Hemnet Group AB rounded out the top three leaders on Tuesday, with ...

Bavarian Nordic’s stock dropped around 10% on the Danish stock exchange Tuesday after reporting disappointing 2024 sales despite a rise of demand for its mpox vaccines.

COPENHAGEN - Bavarian Nordic A/S (OMX:CSE:BAVA) shares fell 10% after the Danish vaccine maker reported preliminary 2024 results and provided 2025 guidance that failed to impress investors. The ...

Financial guidance for 2025 in line with the Company's 2024-2027 ambitions. COPENHAGEN, Denmark, February 3, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced preliminary, unaudited financial ...

Travel Health business demonstrated strong growth of 22%.Additional mpox vaccine orders during outbreak drove higher revenues ...